Open AccessCost-effectiveness of surgery for drug-resistant temporal lobe epilepsy in the US
Author(s) -
Shehryar Sheikh,
Michael W. Kattan,
Michael P. Steinmetz,
Mendel E. Singer,
Belinda Udeh,
Lara Jehi
Publication year - 2020
Publication title -
neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.91
H-Index - 364
eISSN - 1526-632X
pISSN - 0028-3878
DOI - 10.1212/wnl.0000000000010185
Subject(s) - medicine , epilepsy surgery , cost effectiveness , epilepsy , referral , health care , quality adjusted life year , quality of life (healthcare) , surgery , general surgery , emergency medicine , intensive care medicine , psychiatry , family medicine , nursing , risk analysis (engineering) , economics , economic growth
Surgery is an effective but costly treatment for many patients with drug-resistant temporal lobe epilepsy (DR-TLE). We aim to evaluate whether, in the United States, surgery is cost-effective compared to medical management for patients deemed surgical candidates and whether surgical evaluation is cost-effective for patients with DR-TLE in general.